No Data
No Data
Mengke Pharmaceutical (688373.SH): The ban on 2.631 million restricted shares was lifted on April 23
Gelonghui, April 12丨Mengke Pharmaceutical (688373.SH) announced that the total number of shares in circulation during the current stock listing was 2.631 million shares. The stock listing and circulation date is April 23, 2024.
Mengke Pharmaceutical (688373.SH): Shareholders, directors and executives completed a plan to increase their shareholding in the company
Gelonghui, April 12, 丨 Mengke Pharmaceutical (688373.SH) announced that as of April 11, 2024, the increase holder had accumulated 569,800 shares of the company's shares through centralized bidding through the Shanghai Stock Exchange trading system, accounting for 0.087% of the company's total share capital, with a total increase of 2,951,649 yuan. The implementation of this holdings increase plan has been completed. Entities of this increase include some shareholders, directors and senior management of 5% or more of the company, including: MICURX (HK) LIMITED (hereinafter referred to as “Mengke Hong Kong”), the chairman of the company
Mengke Pharmaceutical (688373.SH): Relevant shareholders increased their total shares by 0.04%
Gelonghui, April 8, 丨 Mengke Pharmaceutical (688373.SH) announced that as of April 8, 2024, the increase holder had accumulated 269,800 shares of the company's shares through centralized bidding through the Shanghai Stock Exchange trading system, accounting for 0.04% of the company's total share capital. The total amount of increase in holdings was 13.297.39 million yuan, which has exceeded 50% of the lower limit of 500,000 shares in this increase plan. The implementation of this holdings increase plan has not yet been completed, and the entities that have increased their holdings will continue to implement the holdings increase in accordance with the holdings increase plan. The entities of this increase in holdings include some shareholders, directors and senior management personnel of 5% or more, including: Company 5
Mengke Pharmaceutical (688373): Revenue is in line with expectations, and the research pipeline continues to advance
Incident: The company released its 2023 annual report. The company achieved revenue of 90.78 million yuan (+88.3%) and net profit to mother of -420 million yuan. Contezolamide revenue is growing rapidly. The rapid annual revenue growth rate is mainly due to continued release of contizolamide
Mengke Pharmaceutical (688373): Annual revenue is basically in line with expectations, focusing on clinical promotion of more products
The 2023 results are basically in line with our expectations. The company announced the 2023 results: operating income of RMB 90.78 million, an increase of 88.3% over the previous year; net profit to mother - RMB 421 million, which is basically in line with my 23 year results
Mengke Pharmaceutical (688373): Continued commercialization potential of contizolamide continues to be realized and the R&D pipeline is progressing steadily
Investment highlights: Event: The company released its 2023 annual report, achieved annual revenue of 97.7764 million, an increase of 88.31% over the previous year, and achieved net profit of -421 million yuan, compared to -220 million in the same period last year; single
No Data